Thank you for submitting your manuscript to the EMBO Journal. Three referees were asked to review your manuscript and their comments to the authors are provided below. As you can see, while Referee #3 is not persuaded that the present work provides strong enough data in support for a role for XBP-1 in BCR signaling and B cell differentiation independent of its role in UPR, both referee #1 and #2 are more supportive of the analysis and find that the present work makes an important contribution to the field. Given the support provided by referee #1 and 2, I will go with their recommendation and ask you to submit a suitably revised manuscript for our consideration. When you prepare your revised manuscript please also respond to and address where possible the specific concerns brought up by referee #3. When you send us your revision, include a cover letter with an itemised list of all changes made, or your rebuttal, in response to comments from review.
in B cells when they differentiate, showing that the generation of the spliced form of XBP-1 is independent of the unfolded protein response. In the absence of XBP-1 BCR signaling is defective XBP-1 deficient B cells however can be induced to differentiate into plasmablasts but fail to efficiently colonize the bone marrow.
The most important message in this paper is one that is well supported and unexpected: the induction of XBP-1 is not the result of the accumulation of misfolded secretory immunoglobulins. Another important observation is that in the absence of XBP-1 there is no obvious accumulation of misfolded proteins. These findings are very important since they contradict prevailing hypotheses regarding the function of XBP-1.
There are some other interesting observations that remain to be more mechanistically addressed but may well be further analyzed in future studies. It remains unclear why BCR signaling is defective in the absence of XBP-1. Evidence is provided for feedback regulation of IRE-1 by XBP-1, but how exactly this occurs remains to be elucidated. Overall this is a very interesting manuscript.
Referee #2 (Remarks to the Author):
The transcription factor XBP1 is known to have an important role in the late phases of B cell development. The paper in question reports on a careful comparison of wildtype and XBP1 knockout B cells in vivo and in vitro. Its key observations touch on two aspects: The connection between ER stress and XBP1 signaling and the role of XBP1 as an effector of B cell differentiation. The most definitive findings relate to the second process, and XBP1's role in BCR signaling and cellular dynamics is revealed at new level of detail. This reviewer can only complement the authors on the robustness of their experimental model, the quality of the data and the clarity of the writing. In regard to the link between ER stress and XBP1 activation late in B cell development it is worth noting that the subordination of XBP1 to IRE1 catalytic activity is a feature conserved from yeast to man. In simpler organisms XBP1 plays an important role in matching the capacity of the ER to the load of unfolded proteins entering the organelle. In B cells too, the only form of XBP1 detectable is that encoded by the spliced form of the XBP1 mRNA. Thus it seems reasonable that most, if not all XBP1 function is dependent on IRE1 activity. This state of affairs has suggested an influential model, whereby XBP1's pervasive role in B cell development and plasma cell function/survival reflects the recruitment of an ancient stress pathway to serve a developmental process. At one level the question is already answered: As most/all the XBP1 protein originates from spliced mRNA, the ancient pathway is clearly engaged during B cell development. However, the unresolved issue this paper addresses is whether this ancient stress pathway is being recruited by canonical or non-canonical mechanisms. That is to ask whether B cell development-dependent increase in the ratio of client proteins to chaperones in the ER (i.e. ER stress) does or does not have an important instructive role in eliciting XBP1 signaling to accomplish the downstream events depicted in the second part of the paper. Due to limitations in the tools available to measure the magnitude of the mismatch between chaperones and clients, it is difficult to be sure if an increase in levels of ER stress is or is not the driver of XBP1 activation during B cell differentiation. Attempts to address this question by correlating the temporal profile of changes in client protein load with XBP1 activation are flawed because they fail to take into account the capacity of the ER; because of limited capacity of the ER in naïve B cells, detectable (IRE1-dependent) XBP1 activation may be preceded by an undetectable increase in production of secreted proteins. Furthermore, it is perfectly possible that undetectable increases in the trafficking of clients, other than secreted IgM, may serve as the critical stimuli for canonical XBP1 activation in the undeveloped ER of LPS-stimulated naïve B cells. Thus, the lack of an effect of muS deletion on XBP1 expression early in LPS stimulation is NOT a refutation of the instructive role of ER stress in XBP1 activation. Nonetheless, the authors make a compelling case for considering the possibility that alternative, non-canonical mechanisms for IRE1 activation, are at play late in B cell development. Even without the elaborate phenotypic characterization of BCR signaling in XBP1 mutant cells, this well supported suggestion should render the paper of considerable general interest. Few specific comments: 1) In figure 2B , the expression of XBP1s in LPS-treated cells of muS(+) MD4 and secretory chain minus muS(-) genotypes is shown in different panels. A side-by side comparison of XBP1 expression in the LPS-treated muS(+) and muS(-) cells is lacking. In fact, one gets the impression that XBP1s levels continue to increase through day 4 in the muS(+) cells but begin to decline in the muS(-) cells. This is consistent with the idea that early in the LPS-induction procedure other secreted proteins burden the ER and later secreted IgM dominates. Thus, the experiment shown is not all that supportive of the uncoupling of the expression of secreted IgM (and its presumptive role as an unfolded protein that activates IRE1 by conventional mechanisms) and XBP1 splicing.
2) It is interesting that the defect in BCR signaling of XBP1 knockout cells is most conspicuous four days after LPS ( Figure 4E ), a point in time at which the muS(+) and muS(-) cells begin to diverge in terms of levels of XBP1 ( Figure 2B ). If anything, this argues that secreted IgM (and therefore ER stress->IRE1-> XBP1) is a driver of this differentiation related signal.
Referee #3 (Remarks to the Author):
XBP-1 is a transcription factor initially identified as having an important role in B-cell differentiation and subsequently found to have an important role in the response to unfolded proteins. This manuscript pursues the hypothesis that XBP-1 functions in plasma cell differentiation and antibody secretion as through signaling through the B-cell receptor. The authors have utilized novel animal models to determine the role of XBP-1 in plasma cell differentiation. A CD-19 Cre (bcell specific) conditional XBP-1 KO was crossed with a transgenic MD4 mouse creating an XBP-1 KO B-cell lineage specific for the HEL antigen. This facilitated investigation of B-cell response to antigen in the XBP-1 deficient setting. Another model utilizing Blimp-1 GFP in the same XBP-1 deficient mice permitted evaluation of timing and localization of Blimp-1 activation. The role of XBP-1 KO in plasma cells and its role in bone marrow localization demonstrated a role for CXCL12 and ERK1/2 through interference with CXCR4.
A. The manuscript provides some evidence of a role for XBP-1 in signaling through the B-cell receptor but concludes that this supercedes or eliminates a role of XBP-1 in folding. There is little evidence presented that convincingly refutes the role of XBP-1 splicing as a mediator of the canonical unfolded protein response in the plasma cell. B. XBP-1 is shown to be induced prior to an increase in protein folding load. This however has been previously reported and XBP-1 has been shown to be a downstream of Blimp-1. Previous reports have suggested that XBP-1 activation prior to the onset of increased protein translation may represent a mechanism for B-cells to prepare for the increased folding load and minimize the ER stress induced by differentiation into immunoglobulin secreting cells. C. This paper relies heavily on the XBP-1 conditional KO and would benefit from a supplemental figure demonstrating that the KO was complete or near complete. D. The authors have not adequately shown that lack of XBP-1 does not disrupt protein folding and secretion. Pulse chase, glycosylation, and co-precipitation studies with calreticulin demonstrated little difference between the XBP KO and wild type. Thapsigargin was shown to induce copious aggregation but this stimulus while no aggregates were seen in the XBP-1 KO. In plasma cell differentiation it is likely that the ER is under much less stress and would attenuate its unfolded protein load through decreasing transcription and translation of Ig and induction of ERAD. This could explain decreased Ig secretion but was not investigated. Membrane bound Ig was examined however, total intracellular Ig should also be assessed as Ig may be retained, if not in frank aggregates. E. The role of the canonical UPR has not been sufficiently determined in these models. IRE1 is increase in the XBP-1 KO but other UPR mediators such as eif2 phosphorylation, ATF6 cleavage, GRP78 induction and CHOP activation may compensate for XBP KO. Before suggesting that XBP-1 acts through signaling and not UPR it would be important to assess the relative ER stress in the XBP-1 KO and control through thorough examination of these markers.
In summary this manuscript suggests a role for XBP-1 in B-cell receptor signaling and B-cell differentiation independent of its role in UPR. The evidence that this is not related to XBP-1 role in UPR is not sufficient and the idea that XBP-1 is necessary for signaling in the B-cell and not increasing protein folding and secretory capacity is not supported by the data. The role of XBP-1 in homing of plasma cells to the bone marrow is interesting but needs more careful evaluation. We recommend this manuscript not be published in EMBO. Thanks for the opportunity to review this manuscript. Referee #1 (Remarks to the Author):
In this study by Hu et al., the authors show that in B cells that cannot secrete IgM, XBP-1 is induced in B cells when they differentiate, showing that the generation of the spliced form of XBP-1 is independent of the unfolded protein response. In the absence of XBP-1 BCR signaling is defective XBP-1 deficient B cells however can be induced to differentiate into plasmablasts but fail to efficiently colonize the bone marrow.
We thank the reviewer for these comments.
The transcription factor XBP1 is known to have an important role in the late phases of B cell development. The paper in question reports on a careful comparison of wildtype and XBP1 knockout B cells in vivo and in vitro. Its key observations touch on two aspects: The connection between ER stress and XBP1 signaling and the role of XBP1 as an effector of B cell differentiation. The most definitive findings relate to the second process, and XBP1's role in BCR signaling and cellular dynamics is revealed at new level of detail. This reviewer can only complement the authors on the robustness of their experimental model, the quality of the data and the clarity of the writing.
We appreciate the reviewer's assessment.
In regard to the link between ER stress and XBP1 activation late in B cell development it is worth noting that the subordination of XBP1 to IRE1 catalytic activity is a feature conserved from yeast to man. In simpler organisms XBP1 plays an important role in matching the capacity of the ER to the load of unfolded proteins entering the organelle. In B cells too, the only form of XBP1 detectable is that encoded by the spliced form of the XBP1 mRNA. Thus it seems reasonable that most, if not all XBP1 function is dependent on IRE1 activity. This state of affairs has suggested an influential model, whereby XBP1's pervasive role in B cell development and plasma cell function/survival reflects the recruitment of an ancient stress pathway to serve a developmental process. At one level the question is already answered: As most/all the XBP1 protein originates from spliced mRNA, the ancient pathway is clearly engaged during B cell development. However, the unresolved issue this paper addresses is whether this ancient stress pathway is being recruited by canonical or non-canonical mechanisms. That is to ask whether B cell development-dependent increase in the ratio of client proteins to chaperones in the ER (i.e. ER stress) does or does not have an important instructive role in eliciting XBP1 signaling to accomplish the downstream events depicted in the second part of the paper. Due to limitations in the tools available to measure the magnitude of the mismatch between chaperones and clients, it is difficult to be sure if an increase in levels of ER stress is or is not the driver of XBP1 activation during B cell differentiation. Attempts to address this question by correlating the temporal profile of changes in client protein load with XBP1 activation are flawed because they fail to take into account the capacity of the ER; because of limited capacity of the ER in naïve B cells, detectable (IRE1-dependent) XBP1 activation may be preceded by an undetectable increase in production of secreted proteins. Furthermore, it is perfectly possible that undetectable increases in the trafficking of clients, other than secreted IgM, may serve as the critical stimuli for canonical XBP1 activation in the undeveloped ER of LPS-stimulated naïve B cells. Thus, the lack of an effect of muS deletion on XBP1 expression early in LPS stimulation is NOT a refutation of the instructive role of ER stress in XBP1 activation.
Despite an extensive search, we found no evidence for misfolded proteins in XBP-1-deficient B cells. However, we cannot formally rule out the possibility that some protein misfolding occurs and that we failed to detect it. Until a protein is found that shows folding defects in XBP-1-deficient cells, this search could well turn out to be endless, if indeed we follow the refereeís argument that such accumulation could be due to "undetectable increases." Obviously it would be impossible to detect "undetectable increases." We have included in our discussion a clarification to this effect.
Nonetheless, the authors make a compelling case for considering the possibility that alternative, non-canonical mechanisms for IRE1 activation, are at play late in B cell development. Even without the elaborate phenotypic characterization of BCR signaling in XBP1 mutant cells, this well supported suggestion should render the paper of considerable general interest. Few specific comments: 1) In figure 2B , the expression of XBP1s in LPS-treated cells of muS(+) MD4 and secretory chain minus muS(-) genotypes is shown in different panels. A side-by side comparison of XBP1 expression in the LPS-treated muS(+) and muS(-) cells is lacking. In fact, one gets the impression that XBP1s levels continue to increase through day 4 in the muS(+) cells but begin to decline in the muS(-) cells. This is consistent with the idea that early in the LPS-induction procedure other secreted proteins burden the ER and later secreted IgM dominates. Thus, the experiment shown is not all that supportive of the uncoupling of the expression of secreted IgM (and its presumptive role as an unfolded protein that activates IRE1 by conventional mechanisms) and XBP1 splicing.
We have now added a new Fig. S1 to compare XBP-1 activation side-by-side, as suggested by the reviewer. The levels of XBP-1 do decrease in muS(-) after 4 days in culture, while the levels of XBP-1 in the MD4 cells do not decrease (shown in both figure 2B and S1). However, this does not in any way affect our interpretation of the experiment. B cells may well have multiple mechanisms for ensuring that XBP-1 is expressed, one that acts at an early stage of plasma cell development and is independent of the excess of the unfolded secreted IgM, and a maintenance pathway that may be important in sustaining high levels of XBP1 through later stages of plasma cell development that requires secreted IgM (and this is lacking in the muS(-) mice). The fact that similar levels of spliced XBP-1 are present in MD4 and muS(-) cells at any stage of development suggests that these processes are at least in part uncoupled. We have included a statement to this effect in our revised discussion.
In the new supplemental figure S1, we show that IRE-1 activation in muS(-) occurs earlier than that in the muS(+), further confirming our proposal that secreted IgM is unlikely to be the driver for the activation of IRE-1 and XBP-1.
A. The manuscript provides some evidence of a role for XBP-1 in signaling through the B-cell receptor but concludes that this supercedes or eliminates a role of XBP-1 in folding. There is little evidence presented that convincingly refutes the role of XBP-1 splicing as a mediator of the canonical unfolded protein response in the plasma cell.
There is no disagreement that IRE-1 activation (the activator of the canonical UPR) is responsible for the generation of XBP1 (spliced). However, there is no direct evidence that misfolded proteins trigger the UPR, as is often assumed. Almost without fail such conclusions are based on treatment of cells with toxic drugs, as distinct from more physiological means of engaging the UPR. We feel that adding a previously unexpected and unappreciated role for XBP-1 in BCR signaling and transcription factor regulation represents an important advance in the field.
B. XBP-1 is shown to be induced prior to an increase in protein folding load. This however has been previously reported and XBP-1 has been shown to be a downstream of Blimp-1. Previous reports have suggested that XBP-1 activation prior to the onset of increased protein translation may represent a mechanism for B-cells to prepare for the increased folding load and minimize the ER stress induced by differentiation into immunoglobulin secreting cells.
There is no disagreement that XBP-1 can be induced prior to increased protein load in the ER and we did in fact cite the appropriate papers in the original manuscript. Our findings focus on the idea that secreted IgM is unlikely to be the inducer for XBP-1 activation, as was previously proposed and widely claimed in all of the pertinent reviews on the subject.
The relationship between XBP-1 and Blimp-1 is not as clear as the reviewer implies. Microarray analyses on Blimp-1-deficient B cells suggested that XBP-1 expression requires Blimp-1, and thus placed XBP-1 downstream of Blimp-1 (Shaffer et al., 2002) . XBP-1 was proposed to act upstream of Blimp-1 and IRF4 because XBP-1 activation was normal in B cells from Blimp-1GFP/GFP mice, in which the Blimp-1 functional domain was replaced by green fluorescence protein (Kallies et al., 2007; Klein and Dalla-Favera, 2007) . Our results show that the normal function of both IRF4 and Blimp-1 requires the presence of spliced XBP-1, and thus places XBP-1 downstream of these two transcription factors. Importantly, our data establish a previously unknown feedback loop between XBP-1s and Blimp-1.
C. This paper relies heavily on the XBP-1 conditional KO and would benefit from a supplemental figure demonstrating that the KO was complete or near complete.
The immunoblot data show no detectable XBP-1s protein ( Fig. 2B and S1 ). These cells also fail to become immunoglobulin-secreting cells. (Reimold et al., 2001; Tirosh et al., 2005) . Also, XBP-1 is dispensable for degradation of glycoproteins (Tirosh et al., 2005) . Igalpha, Igbeta, IgM can all traverse the secretory pathway without signs of retention in the absence of XBP1.
E. The role of the canonical UPR has not been sufficiently determined in these models. IRE1 is increase in the XBP-1 KO but other UPR mediators such as eif2 phosphorylation, ATF6 cleavage, GRP78 induction and CHOP activation may compensate for XBP KO. Before suggesting that XBP-1 acts through signaling and not UPR it would be important to assess the relative ER stress in the XBP-1 KO and control through thorough examination of these markers.
XBP-1 deficiency in B cells leads to a failure to become plasma cells, and clearly the other axes of the UPR cannot compensate for this defect. A previous report demonstrated that the PERK pathway
is not required for plasma cell differentiation (Gass et al., 2008) . Likewise, we found that the XBP-1 deficiency has no effect on the levels of eIF2alpha in the course of B cell differentiation. We have now included these data in Fig. S1 .
In summary this manuscript suggests a role for XBP-1 in B-cell receptor signaling and B-cell differentiation independent of its role in UPR. The evidence that this is not related to XBP-1 role in UPR is not sufficient and the idea that XBP-1 is necessary for signaling in the B-cell and not increasing protein folding and secretory capacity is not supported by the data. The role of XBP-1 in homing of plasma cells to the bone marrow is interesting but needs more careful evaluation. We recommend this manuscript not be published in EMBO. Thanks for the opportunity to review this manuscript. , J.N., Jiang, H.Y., Wek, R.C., and Brewer, J.W. (2008) . The unfolded protein response of Blymphocytes: PERK-independent development of antibody-secreting cells. Molecular immunology 45, 1035 -1043 . Kallies, A., Hasbold, J., Fairfax, K., Pridans, C., Emslie, D., McKenzie, B.S., Lew, A.M., Corcoran, L.M., Hodgkin, P.D., Tarlinton, D.M., et al. (2007 . Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 26, 555-566. Klein, U., and Dalla-Favera, R. (2007) . Unexpected steps in plasma-cell differentiation. Immunity 26, 543-544. Reimold, A.M., Iwakoshi, N.N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., Gravallese, E.M., Friend, D., Grusby, M.J., Alt, F., and Glimcher, L.H. (2001) . Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300-307. Shaffer, A.L., Lin, K.I., Kuo, T.C., Yu, X., Hurt, E.M., Rosenwald, A., Giltnane, J.M., Yang, L., Zhao, H., Calame, K., et al. (2002) . Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17, 51-62. Tirosh, B., Iwakoshi, N.N., Glimcher, L.H., and Ploegh, H.L. (2005) . XBP-1 specifically promotes IgM synthesis and secretion, but is dispensable for degradation of glycoproteins in primary B cells.
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